Mohammad A. Obeid

CAR T-Cell Therapy in Hematological Malignancies: Mechanisms, Innovations, and Challenges

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed or refractory hematological malignancies, producing deep and durable responses in B-cell acute lymphoblastic leukemia, aggressive B-cell non-Hodgkin lymphomas, and multiple myeloma. Nevertheless, antigen escape, limited in vivo per...

Advances in Nanocarrier Drug Delivery Systems for the Treatment of Systemic Lupus Erythematosus

Although further investigation is needed to address safety and translational barriers, continued development of nanomedicine platforms holds significant potential to improve disease control and enhance the quality of life for patients with SLE.

Niosomal Encapsulation of Geraniol Improves Antimicrobial Activity Against Selected Foodborne Pathogens

Nose-to-Brain Nanocarriers for Migraine Management: A Comprehensive Review of Drug Delivery Strategies and Translational Challenges.

Despite the proven success of preclinical studies on the delivery of migraine drugs loaded with nanocarriers loaded with antimigraine agents and delivered by the IN route, there is still a shortage in translating this success into the clinical stage.

Exploring the therapeutic potential of NCX1 in hematological cancers; integration of molecular docking, bioinformatics approaches, and experimental validation.

Findings have demonstrated NCX1 as a biologically informative marker of myeloid differentiation and a promising therapeutic weak point within calcium signaling networks in hematological malignancies, providing a rationale for future functional and single-cell validation studies.